主页 > 医学讨论 >
【medical-news】每周使用紫杉醇 延长乳腺癌患者生
每周使用紫杉醇延长乳腺癌患者生命
Finding should change standard of care, which is 4 doses every 3 weeks, researchers say
研究员说该发现将改变每3周4次给药的治疗标准。
By Amanda Gardner
HealthDay Reporter
WEDNESDAY, April 16 (HealthDay News) -- Women who take the drug Taxol weekly after receiving chemotherapy for 12 weeks live longer and live longer without a recurrence of their breast cancer, compared to women who take four taxol treatments every three weeks.
星期三，4月16日（健康日新闻）-与每3周4次紫杉醇治疗的妇女相比，接受每周一次连续12次紫杉醇化疗的妇女活得更长，并且不伴乳腺癌的复发。
The study also evaluated another drug in the same family, called Taxotere (docetaxel), but found that weekly Taxol (paclitaxel) was more effective.
该研究在同一家族中也评价了另一药物，泰索帝（紫杉萜），但发现每周一次紫杉醇更加有效。
"The findings suggest that weekly Taxol for 12 weeks is more effective than four cycles of Taxol and should be considered a new standard," said study author Dr. Joseph A. Sparano. The findings are detailed in the April 17 issue of the New England Journal of Medicine.
“这一发现提示每周一次连续12周的紫杉醇比紫杉醇的四周期疗法更有效，并且应被考虑为新的标准，”该研究的作者Joseph A. Sparano博士说道。这一发现发表在4月17日《新英格兰医学杂志》上。
Prior to this study, four cycles of Taxol was considered the standard, although many oncologists were administering the drug weekly.
该研究以前，紫杉醇的四周期疗法被认为是标准疗法，尽管许多肿瘤科医师采用每周给药。
"We have been using Taxol weekly for at least a year," said Dr. Kumud Tripathy, a clinical assistant professor of internal medicine at Texas A & M Health Science Center College of Medicine and an oncologist with the Bryan-College Station Cancer Clinic.
“我们采用每周一次紫杉醇至少一年了，”Kumud Tripathy博士说道，他是德克萨斯A & M医学健康科学中心学院的内科学临床副教授和Bryan学院临床肿瘤站的肿瘤学专家。
Women with breast cancer who receive drugs known as taxanes after standard chemotherapy have a substantially reduced risk of recurrence and of death. The other taxane, Taxotere (docetaxel) is more potent than Taxol.
患乳腺癌的妇女接受有名的紫杉烷类药物的标准化疗后能实质性的降低复发和死亡的危险。另一紫杉烷，泰索帝（紫杉萜）比紫杉醇更有效。
About a decade ago, a study showed that adding Taxol to standard chemo reduced the risk of breast cancer recurrence. The drug was subsequently approved in the United States, with the standard of care being four doses once every three weeks.
大约10年前，一项研究显示把紫杉醇加到标准化疗中能降低乳腺癌复发的危险。随后这一药物以每3周4次的治疗标准在美国被批准。
A later study showed that giving the same dosage every two weeks was more effective than every three weeks, so that became common practice.
稍后的研究显示每两周给予同样的剂量比每三周更有效，以致变成了普遍的实践。
In the meantime, questions were raised as to whether taxanes were effective for the most common type of breast cancer, or that which is hormone-receptor positive and HER2-negative.
同时，也引起了关于紫杉烷类是否对乳腺癌最常见的类型，或激素受体阳性和HER2阴性类型有效的疑问。
"It raised a lot of concerns," said Sparano, director of breast evaluation center at Montefiore-Einstein Cancer Center in New York City. "People were saying, 'Wait a minute. We thought Taxol was very effective, and maybe it's not as effective as we thought, and are we treating people unnecessarily?'"
“它引起了许多的关注，”Sparano说到，他是纽约蒙特菲尔-爱因斯坦癌症中心乳房评价中心主任。“人们说，‘等一下，我们认为紫杉醇非常有效，或许它并不如我们想像的那么有效，我们治疗人们是不必要的吗？’”
Here, Sparano and his colleagues compared the effectiveness of giving standard chemo (doxorubicin and cyclophosphamide at three-week intervals) plus four cycles or doses of Taxol every three weeks versus every week for 12 doses at a lower dose. They also compared Taxol with Taxotere (four cycles every three weeks) or Taxotere given either every three weeks for four treatments or weekly for 12 treatments. The study involved almost 5,000 women.
这里，Sparano和他的同事比较了给予标准化疗（阿霉素和环磷酰胺间隔三周）加四周期或者更低浓度的紫杉醇每三周与每周连续12次的有效性。他们也比较了紫杉醇和泰索帝（四个化疗周期每三周一次）或泰索帝每3周4次治疗或每周一次共12次治疗。该研究涉及到几乎5000妇女。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-11-06 17:11
医学,生命科学网